Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib

Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib

Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in an international clinical trial sponsored by AbbVie, focusing on a PARP inhibitor called Veliparib to treat ovarian...

Pin It on Pinterest